Fidelity Investments
PYXS icon

Fidelity Investments’s Pyxis Oncology PYXS Stock Holding History

Fidelity Investments’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.3K Buy
12,383
+471
+4% +$901 ﹤0.01% 4432
2026
Q1 		$17.4K Sell
11,912
-946
-7% -$1.43K ﹤0.01% 4567
2025
Q4 		$14.8K Sell
12,858
-2,597
-17% -$9.16K ﹤0.01% 4594
2025
Q3 		$34.3K Sell
15,455
-79,391
-84% -$114K ﹤0.01% 4141
2025
Q2 		$104K Buy
94,846
+8,191
+9% +$9.23K ﹤0.01% 3594
2025
Q1 		$84.9K Buy
86,655
+1,767
+2% +$2.36K ﹤0.01% 3628
2024
Q4 		$132K Buy
84,888
+80,916
+2,037% +$233K ﹤0.01% 3429
2024
Q3 		$14.6K Buy
+3,972
New +$13.9K ﹤0.01% 4306
2024
Q2 		– Sell
-1
Closed -$4 – 5584
2024
Q1 		$4 Buy
+1
New +$4 ﹤0.01% 5310
2023
Q4 		– Sell
-346
Closed -$688 – 5608
2023
Q3 		$688 Buy
346
+175
+102% +$405 ﹤0.01% 4689
2023
Q2 		$438 Buy
+171
New +$542 ﹤0.01% 4829
2022
Q4 		– Sell
-855
Closed -$2K – 5537
2022
Q3 		$2K Sell
855
-3
-0.3% -$8 ﹤0.01% 4579
2022
Q2 		$2K Buy
858
+729
+565% +$1.94K ﹤0.01% 4586
2022
Q1 		$1K Buy
+129
New +$943 ﹤0.01% 4836

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments's PYXS Position: Q2 2026 in Review

Fidelity Investments increased its Pyxis Oncology (PYXS) stake by 4% in Q2 2026, buying an estimated $901 and bringing the position to 12,383 shares worth $37.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4432.

Fidelity Investments first reported a position in PYXS in Q1 2022 and has held it in 14 quarters since. The position peaked at $132K in Q4 2024. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Fidelity Investments held 12,383 shares of Pyxis Oncology worth $37.3K as of Q2 2026.
  • Fidelity Investments bought 471 Pyxis Oncology shares in Q2 2026, an estimated $901.
  • Pyxis Oncology made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4432 holding.
  • Fidelity Investments first reported a position in Pyxis Oncology in Q1 2022 and has held it in 14 quarters since.
  • Fidelity Investments's Pyxis Oncology position peaked at $132K in Q4 2024.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.